Wd. Jarvis et al., Evidence that the apoptotic actions of etoposide are independent of c-Jun/activating protein-1-mediated transregulation, J PHARM EXP, 290(3), 1999, pp. 1384-1392
Citations number
45
Categorie Soggetti
Pharmacology & Toxicology
Journal title
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
We recently demonstrated that physiological induction of apoptosis by cytot
oxic sphingolipid messengers proceeds via activating protein-1 (AP1)-depend
ent and AP1-independent mechanisms in U937 human monoblastic leukemia cells
. Here we examine involvement of the stress-activated protein kinase (SAPK)
cascade and API in the initiation of apoptosis in U937 cells by podaphyllo
toxin-derived inhibitors of topoisomerase II. Induction of apoptotic cell d
eath and DNA damage by treatment of U937 cells with etoposide (100 mu M) wa
s associated with phosphorylation and activation of the c-Jun NH2-terminal
kinase (JNK1) SAPK enzymes p46 and p54-JNK2 and transient increases in expr
ession of the transcription factor c-Jun, a primary JNK substrate. These re
sponses were accompanied by a modest, but sustained, recruitment of the mit
ogen-activated protein kinases p42-extracellular signal receptor-activated
kinase (ERK)1 and p44-extracellular signal receptor-activated kinase 2. The
capacity of etoposide to promote double-stranded DNA degradation and cell
death was unaffected by manipulations that interfere with SAPK signaling ou
tflow through c-Jun/AP1, including: 1) pharmacological inhibition of AP1 ac
tivity by diferuloylmethane and 2) molecular ablation of normal c-Jun funct
ion by the Jun dominant-negative mutant TAM-67. Cytotoxicity of the structu
rally related compound teniposide was similarly unaffected. In parallel tri
als, the lethal actions of ceramide (but not of sphingosine) were markedly
diminished by pretreatment with diferuloylmethane or expression of TAM-67,
confirming the effectiveness of these interventions in suppression of SAPK/
AP1-dependent apoptosis. The involvement of API in the proapoptotic actions
of other inhibitors of topoisomerase II activity was also evaluated. Induc
tion of cell death by the anthracyclines daunorubicin, daunorubicin, and id
arubicin was found to be insensitive to pretreatment with diferuloylmethane
or expression of TAM-67. Collectively, the present data indicate that indu
ction of apoptosis by etoposide and related inhibitors of topoisomerase II
is mediated through a cell death pathway that does not require SAPK-depende
nt recruitment of AP1. These findings additionally suggest that activation
of the SAPK represents a consequence, rather than an underlying cause, of e
toposide-induced apoptosis in myeloid leukemia cells.